

# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Ethambutol/Isoniazid/Pyrazinamide/ Rifampicin 275/75/400/150mg tablet/ capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	
Moxifloxacin 100mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	

DS-TB: Drug-Susceptible TB  
EML: Essential Medicines List  
EOI: Expression of Interest  
ERP: Expert Review Panel  
SRA: Stringent Regulatory Authority  
WHO PQ: World Health Organization Prequalification of Medicines Programme  
Version: September 2025

# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Pyrazinamide 400mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Pyrazinamide 500mg tablet/capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifabutin 150mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifampicin 150mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifampicin 300mg capsule	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	No
Rifapentine 150mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion

DS-TB: Drug-Susceptible TB  
EML: Essential Medicines List  
EOI: Expression of Interest  
ERP: Expert Review Panel  
SRA: Stringent Regulatory Authority  
WHO PQ: World Health Organization Prequalification of Medicines Programme  
Version: September 2025

# Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with other Tuberculosis Stakeholders.  
**Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2025)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2025)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 300mg	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifapentine/Isoniazid 300mg/300mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Yes
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion
Rifapentine/Isoniazid/Moxifloxacin/ Pyrazinamide 300/75/100/375mg tablet	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	<div></div>	Ineligible for inclusion

DS-TB: Drug-Susceptible TB  
EML: Essential Medicines List  
EOI: Expression of Interest  
ERP: Expert Review Panel  
SRA: Stringent Regulatory Authority  
WHO PQ: World Health Organization Prequalification of Medicines Programme  
Version: September 2025